To evaluate the efficacy, safety and tolerability of oral treatment with non-pathogenic bacterial lysate of E. coli and E. faecalis cells (Pro-Symbioflor®) in patients with irritable bowel syndrome
| ISRCTN | ISRCTN91813052 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN91813052 |
| EudraCT/CTIS number | 2012-002741-38 |
| Secondary identifying numbers | 4039162 SM13031 |
- Submission date
- 05/03/2014
- Registration date
- 25/03/2014
- Last edited
- 15/12/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Plain English summary of protocol
Background and study aims
Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits. The exact cause of IBS is unknown. Although there is no cure for IBS, there are treatments that attempt to relieve symptoms, including dietary adjustments, medication and psychological interventions. Probiotic therapy has become the first treatment in recent years. Pro-Symbioflor® (made of natural, physiological, non-pathogenic intestinal bacteria) is a type of drug that claims to be effective in the treatment of IBS according to a previous study. IBS was first defined in 1989 but the diagnostic criteria have changed and a new study is needed. The aim of this study is to assess whether Pro-Symbioflor® will reduce the frequency and the severity of IBS symptoms better than taking a dummy treatment (placebo) for people diagnosed with IBS according to the most recent criteria.
Who can participate?
The aim is to recruit about 380 people diagnosed with IBS, male or female, aged ≥ 18 years, in Germany.
What does the study involve?
Participants will be randomly allocated to a treatment group (Pro-Symbioflor®) or a control group (placebo). Participants will be asked to fill in a patient diary daily during the treatment period (26 weeks). There will be a follow-up visit 4 weeks after the end of treatment. Each participant will receive 10 drops (0.71ml) three time a day during the first week, 20 drops (1.42 ml) three time a day in week 2 and 30 drops (2.14 ml) three time a day from week 3 to week 26 (the drug or the placebo depending on the group they belong to).
If participants take selective serotonin reuptake inhibitor (SSRI) drugs, the medication should be constant from 30 days prior to enrolment in the study and throughout the study. If they have to take emergency medications (such as laxatives, anti-spasmodics, anti-diarrhea), the frequency cannot exceed twice a week and this must be recorded in the patient diary.
Participants will also have to fill in several questionnaires throughout the study. Some questionnaires are included in the patient diary.
What are the possible benefits and risks of participating?
Not provided at time of registration.
Where is the study run from?
The study has been set up by the pharmaceutical company SymbioPharm GmbH in Herborn, Germany in collaboration with the national regulatory authority for medicinal products, BfArM, in Germany. The study will be performed by doctors specialised in the treatment of gastrointestinal disorders. There will be about 25 to 30 recruitment sites. The lead centre is the Department of Internal Medicine Martin-Luther-Hospital, Berlin, Germany.
When is the study starting and how long is it expected to run for?
Recruitment is expected to start in April 2014. Participants will be enrolled in the study for a period of one year.
Who is funding the study?
SymbioPharm GmbH in Herborn, Germany.
Who is the main contact?
Prof. Dr. Hubert Mönnikes
h.moennikes@mlk-berlin.de
Contact information
Scientific
Internal Medicine Martin-Luther-Hospital
Caspar-Theyß-Str. 27-31
Berlin
14193
Germany
| Phone | +49 (0)30 89 55 3100 |
|---|---|
| h.moennikes@mlk-berlin.de |
Study information
| Study design | Randomized double-blind placebo-controlled multi-centre parallel group design |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety and tolerability of oral treatment with non-pathogenic bacterial lysate of E. coli and E. faecalis cells (Pro-Symbioflor®) in patients with irritable bowel syndrome |
| Study acronym | SymPro2012 |
| Study objectives | Pro-Symbioflor® is an immunologically active bacterial lysate produced of 1.5-4.5 x 107 bacteria of Escherichia coli DSM 17252 and Enterococcus faecalis DSM 16440. Pro-Symbioflor® is claimed to be effective as an immunomodulatory acting drug in the therapy of irritable bowel syndrome. To prove this, a trial was arranged by the German authorisation authority and the pharmaceutical company to test for the Verum - Placebo superiority in the improvement of the frequency and severity of IBS symptoms in patients with irritable bowel syndrome. In addition the safety and tolerability were to be studied. Additionally, the human gastrointestinal microbiota in IBS patients is part to investigate and also genetic analysis to assess polymorphism of the serotonergic system. According to the current EMA guidance document on IBS, two primary endpoints should be used to assess efficacy. Statistically significant changes must be found in both parameters. An overall responder is defined as a patient, who is classified as responder for both, the IBS Global Assessment of Improvement and the improvement of Abdominal Pain Intensity. The null hypothesis for the responder analysis is pX=pC, and the alternative is pX≠pC. Where pX and pC are the response rates in the experimental group (Pro-Symbioflor®) and the control group (Placebo), respectively. |
| Ethics approval(s) | The Independent Ethics Committee (IEC) at Charité, Berlin, Germany, 13/12/2013 |
| Health condition(s) or problem(s) studied | Irritable bowel syndrome (IBS) with recurrent abdominal pain or discomfort according to S3 Guideline and Rome III criteria |
| Intervention | Patients are randomised to two groups: 1. Pro-Symbioflor®: 1 mL (14 drops orally) of a bacterial lysate containing 1.5-4.5 x 107 bacterial cells of Escherichia coli DSM 17252 and Enterococcus faecalis DSM 16440. Dosage: 10 drops (0.71 mL) three times daily (TID) during week 1 20 drops (1.43 mL) TID in week 2 30 drops (2.14 mL) TID from week 3 to week 26 2. Placebo: Pro-Symbioflor® Placebo - Culture medium without bacteria cells or bacterial lysate given orally Dosage: 10 drops (0.71 mL) three times daily (TID) during week 1 20 drops (1.43 mL) TID in week 2 30 drops (2.14 mL) TID from week 3 to week 24 |
| Intervention type | Other |
| Primary outcome measure | 1. Response rate measured by the IBS Global Assessment of Improvement Scale (IBS-GAI). IBS-GAI response is defined as at least 50% moderate or substantial improvement on the 7-point rating scale during the 24 weeks of treatment 2. Response rate measured by the 11-point numeric rating scale (NRS). Abdominal Pain Intensity response is defined as a decrease in the weekly average of worst abdominal pain of at least 30% compared to baseline for a minimum of 12 of the 24 measurements (i.e. at least 50% improvement of Abdominal Pain Intensity during the 24 weeks of treatment) |
| Secondary outcome measures | 1. Response rate measured by the 7-point IBS Global Assessment of Improvement Scale (IBS-GAI) during the 24 weeks of treatment. Response is defined as at least 75% moderate or substantial improvement or 50% improvement and no worsening during the last 4 weeks of treatment 2. Response rate measured by the 11-point numeric rating scale during the 24 weeks of treatment. Response is defined as ≥30%improvement in Abdominal Pain Intensity weekly response compared to baseline for a minimum of 18 of the 24 measurements (i.e. 75% improvement of Abdominal Pain Intensity) or 50% improvement and no worsening during the last 4 weeks of treatment 3. Change from baseline of the IBS specific Quality of Life questionnaire (IBS-QOL) 4. Change from baseline of the EQ-5D questionnaire 5. Stool frequency / week 6. Number of days with straining during a bowel movement / week 7. Number of days with imperative urge to defecate / week 8. Number of pain-free days / week 9. Adverse events 10. Vital signs 11. Laboratory values (Biochemistry, Haematology) |
| Overall study start date | 01/04/2014 |
| Completion date | 31/12/2018 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 380 (190 per treatment arm) |
| Key inclusion criteria | 1. Male and female outpatients aged ≥ 18 years 2. Diagnosis of irritable bowel syndrome according to Rome III and the current German S3 guideline on IBS 2011 issued by the relevant German medical associations: 2.1. Recurrent abdominal pain (e.g. discomfort, bloating) at least 3 days per month in the last 3 months associated with 2 or more of the following criteria 2.1.1. Improvement with defecation 2.1.2. Onset associated with a change in frequency of stool 2.1.3. Onset associated with a change in form (appearance) of stool 2.2. Significant reduction in the quality of life as per patients estimation 2.3. Symptom related exclusion of relevant differential diagnoses 2.4. Patient seeks medical help because of gastrointestinal symptoms 3. IBS symptom onset ≥ 6 months 4. Negative colonoscopy (≤ 3 years) 5. Female patients of childbearing potential must be either surgically sterilized or use highly effective contraception at least 3 months prior to enrolment with a negative pregnancy test at screening, baseline/day 0 6. No changes in the dose of selective serotonin reuptake inhibitors (SSRI), if applicable, 30 days prior to screening 7. Willingness to refrain from significant changes in diet, fibre intake, fluid intake, or physical activity during trial participation 8. Willingness to refrain from the use of other medications for IBS treatment, including probiotic medication 9. Ability to comply with treatment 10. Sufficient knowledge of German language to understand trial instructions and rating scales 11. Written informed consent prior to enrolment |
| Key exclusion criteria | 1. History of abdominal surgery within the 6 months prior to screening 2. Presence or suspected presence of unstable coronary artery disease, organic gastrointestinal disease, metabollic diseases, or collagen vascular disease within the 6 months prior to screening 3. Lactose intolerance (in doubtful cases, a diagnostic test has to be performed) 4. Abnormal endoscopy/ abdominal ultrasound requiring further investigation 5. Any alarm symptoms including uninvestigated anaemia, rectal bleeding, weight loss, or unresolved fever within the 6 months prior to screening 6. Participation in another clinical trial or use of any investigational drug within 30 days before dosing 7. Evidence of current or recent alcohol or drug abuse within 6 months prior to screening 8. History or evidence of current laxative abuse 9. Continuous abdominal pain for more than 4 hours before bowel movements 10. Pregnancy or breast feeding 11. Any illness or condition that might impact the safety of study drug administration or evaluability of drug effect based on Investigators discretion 12. No consent to recording and processing of pseudonymised data according to legal requirements |
| Date of first enrolment | 01/04/2014 |
| Date of final enrolment | 31/12/2015 |
Locations
Countries of recruitment
- Germany
Study participating centre
14193
Germany
Sponsor information
Industry
Auf den Lüppen 8
Herborn
35745
Germany
| Phone | +49 2772 981 112 |
|---|---|
| kurt.zimmerman@symbio.de | |
"ROR" |
https://ror.org/03d8m2k26 |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 31/12/2019 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal. |
| IPD sharing plan | The current data sharing plans for the current study are unknown and will be made available at a later date |
Editorial Notes
15/12/2016: The publication and dissemination plan and availability of participant level data have been added.
08/12/2016: The overall trial end date has been updated from 31/12/2015 to 31/12/2018.
